Structured Summary:
In patients with heart failure with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes, tirzepatide significantly reduced the risk of adverse heart failure outcomes and improved health status, quality of life, and functional capacity compared to patients without diabetes, though it was associated with less pronounced weight loss compared to those without diabetes under similar interventions.
| PICO | Description |
|---|---|
| Population | Adults with heart failure with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes. |
| Intervention | Tirzepatide treatment aimed at reducing heart failure outcomes and improving health-related quality of life. |
| Comparison | Patients with HFpEF, obesity, but without diabetes undergoing similar intervention. |
| Outcome | Tirzepatide improved health status, quality of life, functional capacity, reduced left ventricular mass, paracardiac fat, and risk of adverse heart failure outcomes in patients with type 2 diabetes, similar to the effect in those without diabetes. However, weight loss was less pronounced for diabetes patients. |
Source: Milton Packer, et al. “Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.” Read article here.
